Opko Health, Inc. - Common Stock (OPK)

NextPlat (NASDAQ: NXPL, NXPLW), a global e-commerce provider, today announced that its original exclusive e-commerce distribution contract with OPKO Health Inc. (NASDAQ: OPK) has been extended for four years and expanded to include additional e-commerce platforms and digital and social media marketing across China. The original agreement allowed NextPlat to sell OPKO Health Europe’s nutraceutical and veterinary products on the Tmall Global e-commerce platform only. According to the announcement, the expanded contract also grants NextPlat the exclusive rights to sell and market OPKO products in Japan.

NextPlat (NASDAQ: NXPL, NXPLW), a global e-commerce provider, today announced that it has expanded its e-commerce development program in China through a new agreement with a leading Chinese healthcare and nutritional products marketing and distribution services partner (the “marketing partner”). According to the update, the marketing partner will provide NextPlat with a full range of creative content, brand marketing and product sales and distribution services and support the company’s exclusive joint e-commerce development agreement with OPKO Health Europe , a subsidiary of OPKO Health, Inc. (NASDAQ: OPK) . “Our unique e-commerce development program was created to provide American companies with turn-key online sales, marketing and distribution access into the large Chinese consumer market without requiring the significant international infrastructure investments typically required,” said Charles M. Fernandez, executive chairman and CEO of NextPlat. “Through the addition of well-established marketing specialists in China, we believe we can provide our clients with a greater array of value-added services which can help drive product awareness and revenue.”

Penny stocks come with outsized risks, but some risks can be mitigated by following the insiders. Insiders aren't going to waste good money on a bad company.

Insiders are buying these stocks, but not all are good buys for investors or bullish traders; avoid stocks with high short interest, no revenue, and no earnings

Charlie Fernandez, CEO of NextPlat, provided an update on the company's latest financial results during an interview with Steve Darling from Proactive.

NextPlat (NASDAQ: NXPL, NXPLW), a global e-commerce provider, today announced that, through a new e-commerce distribution agreement, it will enable the online sales of OPKO Health Europe, a subsidiary of OPKO Health (NASDAQ: OPK) products in China. Under the agreement terms, NextPlat will launch a OPKO Health-branded online storefront on Alibaba Group Holding Limited’s (NYSE: BABA) Tmall Global e-commerce platform in China featuring an assortment of nutraceutical and veterinary products sold and distributed by OPKO Europe. “NextPlat’s focus is to enable companies across an array of high-growth sectors, such as health care and consumer products, to capitalize on the vast opportunities of global e-commerce. Having already successfully built a sizable portfolio of products for human and animal health, we believe OPKO Europe is an ideal customer for our new e-commerce development program,” said Charles M. Fernandez, executive chairman and CEO of NextPlat. “By leveraging our online expertise, capabilities and our expanded relationship with Alibaba, we can uniquely provide OPKO Europe with a reliable and efficient way to quickly begin selling its products online to potentially millions of new consumers in China.”

New E-Commerce Agreement Enables NextPlat to Offer OPKO's Nutraceutical and Veterinary Products for Sale to Chinese Consumers

Investor sentiment remains strong but upcoming tech earnings and an expected interest rate hike may provide more clarity on the short-term outlook for stocks

Diversified healthcare company OPKO Health Inc. (NASDAQ: OPK) shares may be low priced, but its businesses pipeline of treatments and upside potential may

Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that the U.S. Food and Drug Administration (FDA) has approved NGENLA (somatrogon-ghla), a once-weekly, human growth hormone analog indicated for treatment of pediatric patients aged three years and older who have growth failure due to inadequate secretion of endogenous growth hormone. NGENLA is expected to become available for U.S. prescribing in August 2023.

Pfizer Inc. (NYSE: PFE) and OPKO Health, Inc. (NASDAQ: OPK) announced today that the European Commission has granted marketing authorization for the next-generation long-acting recombinant human growth hormone NGENLA™ (somatrogon), a once-weekly injection to treat children and adolescents from 3 years of age with growth disturbance due to insufficient secretion of growth hormone. NGENLA provides pediatric patients, their caregivers and healthcare providers with a new treatment option for growth hormone deficiency (GHD) that reduces the frequency of required injections from once daily to once weekly.

Palm Beach, FL – November 7, 2022 – FinancialNewsMedia.com News Commentary – While there is no cure for pancreatic cancer in the pancreatic cancer treatment market, new treatment options abound, and research is constantly advancing. Pancreatic cancer is 12th the deadliest forms of cancer, with a 5-year survival rate of just 15%. As a result, there […]

Pfizer Inc. (NYSE: PFE) and OPKO Health, Inc. (NASDAQ: OPK) announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) for somatrogon. Somatrogon is an investigational once-weekly long-acting recombinant human growth hormone for the treatment of growth hormone deficiency (GHD) in pediatric patients. Pfizer is evaluating the FDA’s comments and will work with the agency to determine an appropriate path forward.

OPKO Health, Inc. (NASDAQ: OPK) today announced that management will be participating in the 40th Annual J.P. Morgan Healthcare Conference being held virtually January 10-13, 2022. Management will be hosting one-on-one meetings with investors and will be participating in a virtual fireside chat on Wednesday, January 12th at 3:00 p.m. Eastern time.

Rite Aid (NYSE: RAD) and the U.S. Department of Health and Human Services (HHS), together with BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), announced a ‘Back to School’ COVID-19 testing program offering students at New York State public schools the opportunity for free COVID-19 testing prior to or at the start of the 2021-2022 school year. Students will be tested using highly accurate RT-PCR laboratory-based COVID-19 tests.